Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Commitments and Contingent Liabilities (Tables)

v3.19.1
Commitments and Contingent Liabilities (Tables)
 12 Months Ended
Dec. 31, 2018
Commitments and Contingent Liabilities [Abstract]  
Schedule of royalty rate
On net sales of:   %  
●    leukemia related products     3.0  
●    other products     2.5  
●    in certain limited circumstances, rates may be reduced to     2.0  

 

On fixed sublicense income (with no sublicense income on sales by sub licensee):   %  
●    leukemia related products     20.0  
●    other products     15.0  

 

On fixed sublicense income (with sublicense income on sales by sub licensee):   %  
●    leukemia related products     10.0  
●    other products     7.5